Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
ConclusionsDespite the limitations of the evidence base, the numerous analyses conducted have consistently indicated positive outcomes for tepotinib versus the current standard of care.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Epithelial Cancer | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Taxotere